NCT02101944View on ClinicalTrials.gov

Wild-Type Reovirus in Combination With Carfilzomib and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 9, 2014

Primary Completion Date

May 5, 2021

Study Completion Date

May 7, 2024

Conditions

AnemiaRecurrent Multiple MyelomaRefractory Multiple Myeloma

Interventions

DRUG

Carfilzomib

Given IV

DRUG

Dexamethasone

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

BIOLOGICAL

Pelareorep

Given IV

Trial Locations (3)

30322

Emory University Hospital/Winship Cancer Institute, Atlanta

43210

Ohio State University Comprehensive Cancer Center, Columbus

84112

Huntsman Cancer Institute/University of Utah, Salt Lake City

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH

NCT02101944 - Wild-Type Reovirus in Combination With Carfilzomib and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma | Biotech Hunter | Biotech Hunter